17:11 | European ADRs Move Higher in Friday Trading |  |
15:17 | Inovio Pharmaceuticals Says Brain Cancer Combination Therapy Produced Immune Response i.. |  |
26/05 | Sanofi - European Week Against Cancer 2022 - Interview with Santiago Aguirre, Market Le.. |  |
26/05 | SANOFI : FDA approves Dupixent® (dupilumab) as first treatment for adults and children age.. |  |
25/05 | French health body backs new COVID vaccine booster campaign for this autumn |  |
23/05 | Fitch Raises Sanofi's Outlook To Positive From Stable on Transition Plan, Profitability |  |
23/05 | BOLSA DE MADRID : Un punto bajo que cae |  |
23/05 | France's Sanofi Wins US FDA Nod for Eosinophilic Esophagitis Drug |  |
20/05 | Regeneron, Sanofi Receive US FDA Approval of Dupixent for Eosinophilic Esophagitis |  |
20/05 | PRESS RELEASE : FDA approves Dupixent® (dupilumab) as first treatment for adults and child.. |  |
20/05 | PRESS RELEASE : FDA approves Dupixent® (dupilumab) as first treatment for adults and child.. |  |
20/05 | Sanofi's Dupixent wins U.S. approval for bigger use |  |
20/05 | FDA Grants Regeneron Approval for Dupixent in Inflammatory Disorder Treatment |  |
20/05 | SECTOR UPDATE : Health Care Stocks Gain Premarket Friday |  |
20/05 | Sanofi's Xenpozyme Secures Positive Opinion From the European Medicines Agency's CHMP |  |
20/05 | BOLSA DE MADRID : La mini tabla de salvación es china |  |
18/05 | TRANSCRIPT : Sanofi - Special Call |  |
17/05 | Sanofi Announces New Nirsevimab Data Analyses Reinforce Efficacy Against RSV |  |
17/05 | ASCO - New data from fast-growing innovative Oncology pipeline and portfolio to be pres.. |  |
17/05 | MARKETSCREENER'S WORLD PRESS REVIEW : May 17, 2022 |  |
17/05 | Unilever, Uber, Zurich Call For 2035 Ban On Combustion Engines In Europe |  |
16/05 | Sanofi - Sarclisa (isatuximab) combination provides unprecedented median progression fr.. |  |
16/05 | Sarclisa® (isatuximab) combination provides unprecedented median progression free surv.. |  |
16/05 | Sanofi Says Multiple Myeloma Combination Therapy Shows Longer Progression-Free Survival.. |  |
16/05 | BOLSA DE MADRID : Aterrizaje brusco en China |  |
16/05 | Sanofi To Appeal French Court Ruling To Compensate Family For Epilepsy Drug Side Effect.. |  |
16/05 | Sanofi Says Phase 3 Study of Sarclisa Showed Longer Progression-Free Survival |  |
16/05 | Sanofi's Blood Cancer Drug Prolongs Progression-free Survival By 36 Months In Late-stag.. |  |
15/05 | PRESS RELEASE : Sarclisa® (isatuximab) combination provides unprecedented median progressi.. |  |
15/05 | Sarclisa® Combination Provides Unprecedented Median Progression Free Survival in Patien.. |  |
15/05 | PRESS RELEASE : Sarclisa® (isatuximab) combination provides unprecedented median progressi.. |  |
11/05 | Sanofi Says Nirsevimab Showed Nearly 80% Efficacy Against Respiratory Syncytial Virus |  |
11/05 | Sanofi-AstraZeneca's Respiratory Syncytial Virus Drug Shows 80% Efficacy in Pooled Data.. |  |
11/05 | PRESS RELEASE : New nirsevimab data analyses reinforce efficacy against RSV |  |
11/05 | PRESS RELEASE : New nirsevimab data analyses reinforce efficacy against RSV |  |
10/05 | European Stocks Rebound As Volatility Continues to Dominate Markets |  |
10/05 | Rallybio Secures Global Rights to Sanofi's Antibody Candidate to Treat Anemia |  |
10/05 | Acerus Pharmaceuticals Reports Q1 Total Revenue of US$0.8 Million; Company Update and O.. |  |
09/05 | IGM Biosciences Announces Closing of Global Collaboration Agreement with Sanofi |  |
06/05 | Igm Biosciences, Inc. Announces Closing of Global Collaboration Agreement with Sanofi |  |
06/05 | EuroAPI gains on market debut after spin-off from Sanofi |  |
06/05 | Sanofi Spinoff EUROAPI Gains 5% in Euronext Paris Debut |  |
06/05 | BOLSA DE MADRID : Don't Look Up |  |
04/05 | Regeneron's COVID drug sales outside U.S. help revenue beat |  |
04/05 | Will The Supreme Court Take The Bait? CVSG Issued And Other Updates In The Amgen v. San.. |  |
04/05 | FOUNDATION S : Sanofi's new philanthropic spearhead |  |
04/05 | PRESS RELEASE : Foundation S: Sanofi's new philanthropic spearhead |  |
03/05 | Annual General Meeting of May 3, 2022 |  |
03/05 | PRESS RELEASE : Annual General Meeting of May 3, 2022 |  |
03/05 | PRESS RELEASE : Annual General Meeting of May 3, 2022 |  |
03/05 | Sanofi Appoints Approves Appointment of Carole Ferrand, Emile Voest and Antoine Yver as.. |  |
03/05 | Sanofi Approves Cash Dividend, Payable on May 10, 2022 |  |
03/05 | TRANSCRIPT : Sanofi - Shareholder/Analyst Call |  |
02/05 | Denali Therapeutics, Sanofi Start Phase 2 Trial for ALS Inhibitor |  |
02/05 | L'agenda di domani |  |
02/05 | L'agenda della settimana |  |
29/04 | SANOFI : teams up with McLaren Racing to accelerate industrial excellence - Form 6-K |  |
29/04 | L'agenda della prossima settimana |  |
29/04 | Sanofi Teams Up with Mclaren Racing to Accelerate Industrial Excellence |  |
28/04 | SANOFI : Q1 2022 business EPS(1) up 16.1% at CER driven by higher sales and improving marg.. |  |
28/04 | Strong earnings spur rally across European stocks |  |
28/04 | BioMarin Announces Record Revenues in First Quarter 2022 |  |
28/04 | TRANSCRIPT : Sanofi, Q1 2022 Earnings Call, Apr 28, 2022 |  |
28/04 | SANOFI : supera las expectativas del consenso y confirma los objetivos para 2022 |  |
28/04 | SANOFI : Q1 Earnings Snapshot |  |
28/04 | Sanofi mit überraschend starkem Jahresauftakt |  |
28/04 | Sanofi's Q1 Adjusted Earnings, Revenue Rise; Reaffirms 2022 Guidance |  |
28/04 | Sanofi Confident In Full-Year Prospects As Dupixent, Consumer Healthcare Drive Strong F.. |  |
28/04 | BOLSA DE MADRID : La venganza de Meta |  |
28/04 | Sanofi Earnings, Sales Rose in 1Q; Expects Further Growth in 2022 |  |
28/04 | Sanofi steigert Umsatz und Ergebnis |  |
28/04 | INTERIM REPORT Q1/2022 : Our financial targets remain in place |  |
28/04 | Sanofi ziet omzet stijgen |  |
28/04 | Sanofi profit gain beats market view on bestseller drug Dupixent |  |
28/04 | Sanofi's Q1 Profit Soars Over Dupixent's Sustained Performance, Higher Consumer Healthc.. |  |